Gender | Age
Item
female patients, >/= 18 years of age
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Breast cancer recurrent Locally | Secondary malignant neoplasm of female breast
Item
locally recurrent/metastatic breast cancer (relapse in supra- or infraclavicular lymph nodes is regarded as metastatic disease)
boolean
C0278493 (UMLS CUI [1,1])
C1517927 (UMLS CUI [1,2])
C0346993 (UMLS CUI [2])
Disease HER2 Positive
Item
her2-positive primary disease
boolean
C0012634 (UMLS CUI [1,1])
C2348909 (UMLS CUI [1,2])
Herceptin | Adjuvant therapy | Neoadjuvant Therapy
Item
patients must have received herceptin in the adjuvant and/or neoadjuvant setting
boolean
C0338204 (UMLS CUI [1])
C0677850 (UMLS CUI [2])
C0600558 (UMLS CUI [3])
Breast cancer recurrent | Status post Herceptin Discontinuation | Status post Adjuvant Chemotherapy | Status post Neoadjuvant Chemotherapy | HER2-positive carcinoma of breast
Item
relapsed breast cancer >/= 6 months after discontinuing last drugs of herceptin and/or chemotherapy in the adjuvant and/or neoadjuvant setting for her2-positive breast cancer
boolean
C0278493 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C0338204 (UMLS CUI [2,2])
C1444662 (UMLS CUI [2,3])
C0231290 (UMLS CUI [3,1])
C0085533 (UMLS CUI [3,2])
C0231290 (UMLS CUI [4,1])
C0600558 (UMLS CUI [4,2])
C3665472 (UMLS CUI [4,3])
C1960398 (UMLS CUI [5])
Measurable Disease
Item
measurable disease according to recist 1.0
boolean
C1513041 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Doxorubicin Cumulative Dose Maximum | Epirubicin Cumulative Dose Maximum | Anthracyclines Absent
Item
maximum cumulative dose of doxorubicin </= 360 mg/m2 or of epirubicin </= 720 mg/m2 or no prior anthracyclines
boolean
C0013089 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,3])
C0014582 (UMLS CUI [2,1])
C2986497 (UMLS CUI [2,2])
C0806909 (UMLS CUI [2,3])
C0282564 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
Operative Surgical Procedure Previous | Prior radiation therapy
Item
at least 3 weeks after prior surgery or radiotherapy
boolean
C0543467 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0279134 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
pregnant or breastfeeding women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Prior Chemotherapy Secondary malignant neoplasm of female breast
Item
previous chemotherapy for metastatic breast cancer (prior endocrine therapy till progressive disease is allowed)
boolean
C1514457 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
Pleural effusion disorder | Ascites | Bone lesion
Item
pleural effusions, ascites or bone lesions as only manifestation of disease
boolean
C0032227 (UMLS CUI [1])
C0003962 (UMLS CUI [2])
C0238792 (UMLS CUI [3])
Metastatic malignant neoplasm to brain
Item
brain metastases
boolean
C0220650 (UMLS CUI [1])
Invasive cancer | Exception Secondary malignant neoplasm of female breast
Item
invasive malignancy other than metastatic breast cancer
boolean
C0677898 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0346993 (UMLS CUI [2,2])
Bone Marrow function Inadequate | Liver function Inadequate | Renal function Inadequate
Item
inadequate bone marrow, hepatic or renal function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0205412 (UMLS CUI [1,3])
C0232741 (UMLS CUI [2,1])
C0205412 (UMLS CUI [2,2])
C0232804 (UMLS CUI [3,1])
C0205412 (UMLS CUI [3,2])
HER Receptors Targeted Therapy | Exception Herceptin Neo-adjuvant
Item
prior treatment with anti-her therapies other than (neo)adjuvant herceptin
boolean
C3812393 (UMLS CUI [1,1])
C2985566 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0338204 (UMLS CUI [2,2])
C1298676 (UMLS CUI [2,3])